KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview
February 01 2019 - 7:29AM
InvestorsHub NewsWire
Dallas, TX --
February 1, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced a preview presentation scheduled
for next week, on Tuesday, February 5th, to be published
on line by KALY CEO Fred Ferri with Professor Jeffry Osbourn,
Ph.D., from the University of Kentucky. In addition to the
previously disclosed in vitro genomics study to evaluate the impact
of its pharmaceutical grade cannabis extracts in combination with
other therapies on Chronic Obstructive Pulmonary
Disease (COPD) patients, KALY has also competed a long-term,
pilot study on the treatment of COPD in primates with its cannabis
extracts. The preview on Tuesday next week will elaborate further
on the primate study pending a final report on the study coming in
March.
Kali-Extracts, Inc. (“KALY”) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. Similarly, KALY its patented cannabis
extraction technology to develop pharmaceutical products internally
and through partnerships.
KALY has
licensed its extraction process to Puration, Inc. (USOTC: PURA)
(“PURA”) for the production of beverages. With over $1
million in trailing twelve-month sales, PURA’s sales of EVERx CBD
Sports Water are growing. KALY is now working with PURA to
formulate a 25 MG CBD formula for a new CBD infused water
product. Together, PURA and KALY have signed over a $1
million agreement to produce CBD infused water for Generex
Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is
expected to be on shelves soon.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2024 to May 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Puration Inc (CE) (OTCMarkets): 0 recent articles
More Puration Inc. (PC) News Articles